Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
- Author:
Sung‑Hoon JUNG
1
;
Youngil KOH
;
Min Kyoung KIM
;
Jin Seok KIM
;
Joon Ho MOON
;
Chang‑Ki MIN
;
Dok Hyun YOON
;
Sung‑Soo YOON
;
Je‑Jung LEE
;
Chae Moon HONG
;
Ka‑Won KANG
;
Jihyun KWON
;
Kyoung Ha KIM
;
Dae Sik KIM
;
Sung Yong KIM
;
Sung‑Hyun KIM
;
Yu Ri KIM
;
Young Rok DO
;
Yeung‑Chul MUN
;
Sung‑Soo PARK
;
Young Hoon PARK
;
Ho Jin SHIN
;
Hyeon‑Seok EOM
;
Sang Eun YOON
;
Sang Mee HWANG
;
Won Sik LEE
;
Myung‑won LEE
;
Jun Ho YI
;
Ji Yun LEE
;
Ji Hyun LEE
;
Ho Sup LEE
;
Sung‑Nam LIM
;
Jihyang LIM
;
Ho‑Young YHIM
;
Yoon Hwan CHANG
;
Jae‑Cheol JO
;
Jinhyun CHO
;
Hyungwoo CHO
;
Yoon Seok CHOI
;
Hee jeong CHO
;
Ari AHN
;
Jong Han CHOI
;
Hyun Jung KIM
;
Kihyun KIM
Author Information
- Publication Type:REVIEW
- From:Blood Research 2025;60():9-
- CountryRepublic of Korea
- Language:English
- Abstract: Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM.In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treat‑ ment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, thera‑ peutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.
